Literature DB >> 23860354

Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.

Magdalena Nutu1, Henrik Zetterberg, Elisabet Londos, Lennart Minthon, Katarina Nägga, Kaj Blennow, Oskar Hansson, Annika Ohrfelt.   

Abstract

BACKGROUND: The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-β (Aβ)1-42/Aβ1-40 ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD.
METHOD: CSF levels of Aβ1-40 and Aβ1-42 in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays.
RESULTS: The CSF Aβ1-42/Aβ1-40 ratio increased discrimination of AD from PDD and DLB compared with either of the two Aβ biomarkers individually.
CONCLUSION: The use of the Aβ1-42/Aβ1-40 ratio could improve the differentiation of AD from PDD and DLB.
© 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23860354     DOI: 10.1159/000353442

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  17 in total

Review 1.  Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives.

Authors:  Donovan A McGrowder; Fabian Miller; Kurt Vaz; Chukwuemeka Nwokocha; Cameil Wilson-Clarke; Melisa Anderson-Cross; Jabari Brown; Lennox Anderson-Jackson; Lowen Williams; Lyndon Latore; Rory Thompson; Ruby Alexander-Lindo
Journal:  Brain Sci       Date:  2021-02-10

Review 2.  Changes of cerebrospinal fluid Aβ42, t-tau, and p-tau in Parkinson's disease patients with cognitive impairment relative to those with normal cognition: a meta-analysis.

Authors:  Xiaohui Hu; Yan Yang; Daokai Gong
Journal:  Neurol Sci       Date:  2017-08-14       Impact factor: 3.307

Review 3.  Diagnosis of neurodegenerative dementia: where do we stand, now?

Authors:  Giulia M Sancesario; Sergio Bernardini
Journal:  Ann Transl Med       Date:  2018-09

4.  A new structural model of Alzheimer's Aβ42 fibrils based on electron paramagnetic resonance data and Rosetta modeling.

Authors:  Lei Gu; Joyce Tran; Lin Jiang; Zhefeng Guo
Journal:  J Struct Biol       Date:  2016-01-28       Impact factor: 2.867

5.  Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study.

Authors:  Julien Dumurgier; Susanna Schraen; Audrey Gabelle; Olivier Vercruysse; Stéphanie Bombois; Jean-Louis Laplanche; Katell Peoc'h; Bernard Sablonnière; Ksenia V Kastanenka; Constance Delaby; Florence Pasquier; Jacques Touchon; Jacques Hugon; Claire Paquet; Sylvain Lehmann
Journal:  Alzheimers Res Ther       Date:  2015-06-01       Impact factor: 6.982

Review 6.  Biomarkers in biological fluids for dementia with Lewy bodies.

Authors:  Sebastian Schade; Brit Mollenhauer
Journal:  Alzheimers Res Ther       Date:  2014-10-16       Impact factor: 6.982

Review 7.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

8.  Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry.

Authors:  Simon Sjödin; Annika Öhrfelt; Gunnar Brinkmalm; Henrik Zetterberg; Kaj Blennow; Ann Brinkmalm
Journal:  Clin Proteomics       Date:  2016-02-25       Impact factor: 3.988

9.  Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale.

Authors:  Sylvain Lehmann; Constance Delaby; Guilaine Boursier; Cindy Catteau; Nelly Ginestet; Laurent Tiers; Aleksandra Maceski; Sophie Navucet; Claire Paquet; Julien Dumurgier; Eugeen Vanmechelen; Hugo Vanderstichele; Audrey Gabelle
Journal:  Front Aging Neurosci       Date:  2018-05-28       Impact factor: 5.750

Review 10.  Clinical significance of fluid biomarkers in Alzheimer's Disease.

Authors:  Piotr Lewczuk; Marta Łukaszewicz-Zając; Piotr Mroczko; Johannes Kornhuber
Journal:  Pharmacol Rep       Date:  2020-05-08       Impact factor: 3.024

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.